Efficacy of amantadine on behavioural problems due to acquired brain injury: A systematic review

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Objectives: To systematically review literature on efficacy of amantadine on behavior (irritability/aggression/agitation, emotional lability, apathy, impairment of executive functioning), participation, quality-of-life (QoL), and safety, in patients with acquired brain injury (ABI). Amantadine is widely used clinically, so comprehensive information on efficacy, participation, QoL and safety is relevant. Methods: We used PRISMA Guidelines. We searched PubMed/EMBASE/CINAHL (last search 28-8-2018) Two independent reviewers performed selection and data-extraction. Quality of studies was assessed, using CONSORT and Quality Assessment Tool for Quantitative Studies (QATFQS). Results: Eleven out of 500 studies were included. Of five RCTs, two reported significant effects on irritability/aggression, and one no effect. One RCT on cognition no effect. One prospective cohort study showed a significant effect on executive functioning. One retrospective study was inconclusive. One single-case experimental design (SCED) study reported significant effect on apathy and three case-reports indicated effects on behavior. QoL and societal participation were not measured. No safety issues emerged. Conclusion: Amantadine may be efficacious on irritability and aggression after ABI. Amantadine is a safe drug in the presence of adequate creatinine clearance. Future studies should use designs, suitable for the heterogeneous ABI population, like randomized SCEDs, and should include the effect on societal participation and QoL.

Original languageEnglish
Pages (from-to)1137-1150
Number of pages14
JournalBrain Injury
Volume33
Issue number9
Early online date28 Jun 2019
DOIs
Publication statusPublished - 29 Jul 2019

Keywords

  • AGGRESSIVE-BEHAVIOR
  • AGITATION
  • Acquired-brain-injury
  • DISORDERS
  • FRONTAL-LOBE DYSFUNCTION
  • HYDROCHLORIDE
  • IRRITABILITY
  • MANAGEMENT
  • N-OF-1 TRIALS
  • NEUROPSYCHIATRIC SYMPTOMS
  • SINGLE-SUBJECT DESIGNS
  • amantadine
  • behaviour

Cite this

@article{c89da900181d4f6492e1b715dbd267cb,
title = "Efficacy of amantadine on behavioural problems due to acquired brain injury: A systematic review",
abstract = "Objectives: To systematically review literature on efficacy of amantadine on behavior (irritability/aggression/agitation, emotional lability, apathy, impairment of executive functioning), participation, quality-of-life (QoL), and safety, in patients with acquired brain injury (ABI). Amantadine is widely used clinically, so comprehensive information on efficacy, participation, QoL and safety is relevant. Methods: We used PRISMA Guidelines. We searched PubMed/EMBASE/CINAHL (last search 28-8-2018) Two independent reviewers performed selection and data-extraction. Quality of studies was assessed, using CONSORT and Quality Assessment Tool for Quantitative Studies (QATFQS). Results: Eleven out of 500 studies were included. Of five RCTs, two reported significant effects on irritability/aggression, and one no effect. One RCT on cognition no effect. One prospective cohort study showed a significant effect on executive functioning. One retrospective study was inconclusive. One single-case experimental design (SCED) study reported significant effect on apathy and three case-reports indicated effects on behavior. QoL and societal participation were not measured. No safety issues emerged. Conclusion: Amantadine may be efficacious on irritability and aggression after ABI. Amantadine is a safe drug in the presence of adequate creatinine clearance. Future studies should use designs, suitable for the heterogeneous ABI population, like randomized SCEDs, and should include the effect on societal participation and QoL.",
keywords = "AGGRESSIVE-BEHAVIOR, AGITATION, Acquired-brain-injury, DISORDERS, FRONTAL-LOBE DYSFUNCTION, HYDROCHLORIDE, IRRITABILITY, MANAGEMENT, N-OF-1 TRIALS, NEUROPSYCHIATRIC SYMPTOMS, SINGLE-SUBJECT DESIGNS, amantadine, behaviour",
author = "{Ter Mors}, {B J} and Backx, {A P M} and P Spauwen and Ponds, {R W H M} and {Van Harten}, {P N} and {Van Heugten}, {C M}",
year = "2019",
month = "7",
day = "29",
doi = "10.1080/02699052.2019.1631482",
language = "English",
volume = "33",
pages = "1137--1150",
journal = "Brain Injury",
issn = "0269-9052",
publisher = "Routledge/Taylor & Francis Group",
number = "9",

}

Efficacy of amantadine on behavioural problems due to acquired brain injury : A systematic review. / Ter Mors, B J; Backx, A P M; Spauwen, P; Ponds, R W H M; Van Harten, P N; Van Heugten, C M.

In: Brain Injury, Vol. 33, No. 9, 29.07.2019, p. 1137-1150.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Efficacy of amantadine on behavioural problems due to acquired brain injury

T2 - A systematic review

AU - Ter Mors, B J

AU - Backx, A P M

AU - Spauwen, P

AU - Ponds, R W H M

AU - Van Harten, P N

AU - Van Heugten, C M

PY - 2019/7/29

Y1 - 2019/7/29

N2 - Objectives: To systematically review literature on efficacy of amantadine on behavior (irritability/aggression/agitation, emotional lability, apathy, impairment of executive functioning), participation, quality-of-life (QoL), and safety, in patients with acquired brain injury (ABI). Amantadine is widely used clinically, so comprehensive information on efficacy, participation, QoL and safety is relevant. Methods: We used PRISMA Guidelines. We searched PubMed/EMBASE/CINAHL (last search 28-8-2018) Two independent reviewers performed selection and data-extraction. Quality of studies was assessed, using CONSORT and Quality Assessment Tool for Quantitative Studies (QATFQS). Results: Eleven out of 500 studies were included. Of five RCTs, two reported significant effects on irritability/aggression, and one no effect. One RCT on cognition no effect. One prospective cohort study showed a significant effect on executive functioning. One retrospective study was inconclusive. One single-case experimental design (SCED) study reported significant effect on apathy and three case-reports indicated effects on behavior. QoL and societal participation were not measured. No safety issues emerged. Conclusion: Amantadine may be efficacious on irritability and aggression after ABI. Amantadine is a safe drug in the presence of adequate creatinine clearance. Future studies should use designs, suitable for the heterogeneous ABI population, like randomized SCEDs, and should include the effect on societal participation and QoL.

AB - Objectives: To systematically review literature on efficacy of amantadine on behavior (irritability/aggression/agitation, emotional lability, apathy, impairment of executive functioning), participation, quality-of-life (QoL), and safety, in patients with acquired brain injury (ABI). Amantadine is widely used clinically, so comprehensive information on efficacy, participation, QoL and safety is relevant. Methods: We used PRISMA Guidelines. We searched PubMed/EMBASE/CINAHL (last search 28-8-2018) Two independent reviewers performed selection and data-extraction. Quality of studies was assessed, using CONSORT and Quality Assessment Tool for Quantitative Studies (QATFQS). Results: Eleven out of 500 studies were included. Of five RCTs, two reported significant effects on irritability/aggression, and one no effect. One RCT on cognition no effect. One prospective cohort study showed a significant effect on executive functioning. One retrospective study was inconclusive. One single-case experimental design (SCED) study reported significant effect on apathy and three case-reports indicated effects on behavior. QoL and societal participation were not measured. No safety issues emerged. Conclusion: Amantadine may be efficacious on irritability and aggression after ABI. Amantadine is a safe drug in the presence of adequate creatinine clearance. Future studies should use designs, suitable for the heterogeneous ABI population, like randomized SCEDs, and should include the effect on societal participation and QoL.

KW - AGGRESSIVE-BEHAVIOR

KW - AGITATION

KW - Acquired-brain-injury

KW - DISORDERS

KW - FRONTAL-LOBE DYSFUNCTION

KW - HYDROCHLORIDE

KW - IRRITABILITY

KW - MANAGEMENT

KW - N-OF-1 TRIALS

KW - NEUROPSYCHIATRIC SYMPTOMS

KW - SINGLE-SUBJECT DESIGNS

KW - amantadine

KW - behaviour

U2 - 10.1080/02699052.2019.1631482

DO - 10.1080/02699052.2019.1631482

M3 - Review article

C2 - 31250669

VL - 33

SP - 1137

EP - 1150

JO - Brain Injury

JF - Brain Injury

SN - 0269-9052

IS - 9

ER -